A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib 100 mg and 50 mg QD in Adult Participants with Nonsegmental Vitiligo

You may be able to join if

• Participants must be ≥18 years of age at Screening.
• Eligible participants must have at both Screening and BL: • A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and • Body surface area (BSA) involvement between 4%-60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet; and • BSA ≥0.5% involvement on the face (face is defined as including the area on the forehead to the original hairline, on the cheek vertically to the jawline, and laterally from the corner of the mouth to the tragus. The face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids); and • F-VASI ≥0.5 and T-VASI ≥3; and • Either active or stable nonsegmental vitiligo at both Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.